Gender differences and outcome of melanoma patients

Morgese, Francesca; Berardi, Rossana; Sampaolesi, Caterina; Torniai, Mariangela; Marcantognini, Giulia; Giacchetti, Alfredo; Serresi, Stefano; Onofri, Azzurra; Bittoni, Alessandro; Pilone, Alberta; Ricotti, G.; Cascinu, Stefano

doi:10.1186/1479-5876-13-s1-p13

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This predicts that growth will overtake reduction far mere quickly in males, yet the metastasis rates of both genders should not differ. These results are consistent with and present a potential reason for the well-known fact that indeed males have far worse outcomes than females, yet both have similar metastasis rates in melanoma [8,28,29].…”

Section: Discussionsupporting

confidence: 87%

A New Mathematical Model for Tumor Growth, Reduction and Metastasis, Validation with Zebrafish Melanoma and Potential Implications for Dormancy and Recurrence

Heilmann

et al. 2019

Preprint

View full text Add to dashboard Cite

The genetic and environmental heterogeneity associated with tumors makes cancer treatment and recovery a difficult and unpredictable process. Patients with initially similar disease can experience vastly different outcomes including sustained recovery, refractory disease or, remarkably, recurrence years after treatment. Mathematical models informed with animal and human data provide tools for theoretical and clinical understanding of cancer progression and of the causes of highly variant disease outcomes. This work postulates a population balance model to describe how populations of a large ensemble of tumors of different sizes evolve in time. Each tumor can grow or reduce in size and metastasize. Gender-segregated, immune-competent and immune-suppressed translucent zebrafish (Casper variant) were inoculated with a transgenic melanoma cell line expressing human BRAF V600E and GFP and observed for tumor progression and metastasis. The model describes both these fish data sets, full histograms of population number vs size at multiple times for both immune states, and a human hepatocellular carcinoma data set also consisting of multiple time histograms very well with a minimum of cancer-specific parameters. The only zebrafish parameter to show strong gender-dependence was the host-dependent tumor reduction (immunity) parameter. This result significantly predicts that men should have far worse outcomes than females, yet similar metastasis rates, which are both indeed the case in human melanomas. Moreover the dynamic growth -reduction interplay, for certain relationships between these processes' parameters in the model provides a potential mechanism for apparent cancer dormancy and recurrence. Although fish melanoma parameters are not in this range, the model guides future work to try to access it.

show abstract

Section: Discussionsupporting

confidence: 87%

A New Mathematical Model for Tumor Growth, Reduction and Metastasis, Validation with Zebrafish Melanoma and Potential Implications for Dormancy and Recurrence

Heilmann

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…However, our study found that gender did not significantly impact immune response and was not associated with improved clinical outcome. The trend toward improved survival in males is an unexpected finding, as males with melanoma generally have significantly worse outcomes than females, stage-for-stage [35-36]. Gender differences in melanoma histology have been reported, with males having higher rates of ulceration and a more frequent absence of tumor-infiltrating lymphocytes [36].…”

Section: Discussionmentioning

confidence: 99%

Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials’ experience

Ramirez

Wages

et al. 2015

Cancer Immunol Immunother

View full text Add to dashboard Cite

Background The impacts of patient age and gender on immune response (IR) and clinical outcome after cancer vaccines are not known. We hypothesized younger and female patients would have higher IR rates and better survival. Methods Patients with resected stage IIB-IV melanoma in three clinical trials (Mel43, Mel44, Mel48) were vaccinated with 12 melanoma-associated peptides restricted by Class I MHC. The cumulative incidence rate of CD8+ T cell responses (direct Interferon-gamma ELIspot assay) by week 7 was compared by age and gender. Overall survival (OS) and disease-free survival (DFS) landmark analyses were compared by Kaplan-Meier estimates and in multivariate analyses. Results T cell responses were evaluated in 327 patients, and detected in 50% of males and 48% of females, with no difference in IR by gender or menopausal status. Males had trends toward longer DFS (p=0.12) and OS (p=0.09). Cumulative incidence of IR was higher in patients < 64 years of age versus older patients (p=0.03). OS and DFS were similar by age group (p> 0.50). In multivariate modeling, younger age was associated with better IR (OR 0.40, p-value 0.003), without an impact of age or gender on clinical outcomes. Conclusion These data support the hypothesis that older patients are less likely to develop T cell responses to a cancer vaccine. Nonetheless, significant proportions of older patients mount immune responses with comparable survival outcomes. Thus, these data support including older patients in cancer vaccine trials, but suggest value in stratifying patients by age < / > 64 years.

show abstract

“…Other various studies also showed no predilection for either gender, while some had shown greater association with male gender. 18,19 A study that enrolled 1.156 adults diagnosed with melanoma, reported that females has more advantage prognostic factors in melanoma. This study was used amitotic rate of melanomaas the prognostic factor for recurrence, although the results only showed marginally significance data.…”

Section: Discussionmentioning

confidence: 99%

“…16,17 Several studies also showed that the male gender was more affected and associated with tumor recurrence. [18][19][20] While many cases of conjunctival melanoma appeared to be recurrence, there is valid data about parameters to predict the recurrence of this tumor. To date, there is limited study that analyzed the correlation between clinical features of conjunctival melanoma and its recurrences in Indonesia.…”

Section: Introductionmentioning

confidence: 99%

The predictive factor for conjunctival melanoma recurrence

et al. 2019

View full text Add to dashboard Cite

Conjunctival melanoma potentially deadly tumor. While many cases of conjunctival melanoma appeared to be a recurrence, there is no valid data about parameters to predict the recurrence of this tumor. This study intended to evaluate whether histopathologic features can be used as a predictor for recurrence in conjunctival melanoma. This was a retrospective study, involving patients with conjunctival melanoma by the year 2013-1017 in Dr. Sardjito General Hospital and Dr. Yap Eye Hospital, Yogyakarta. Patient's characteristic was determined by age, sex, laterality, tumor size, tumor location, histopathological dominancy, MMC application, recurrence, and metastases. Sixteen cases were found: male (62.5%) and female (37.5%). Age from 5-79 years, mean was 56.19 years. Tumor location was in bulbar in 11 patients (68.7%), palpebral in 5 patients (31.3%).There was significant association between metastasis and the tumor recurrence (OR 13.0; 95% CI 1.9-85.4; p = 0.007). A favorable trend of association was also found between location and the recurrence of melanoma (OR 15.0; 95% CI 0.9-228.8; p = 0.06). In summary, our study showed that the patients that developing distant metastasis were at a greater risk for tumor recurrence.

show abstract

Gender differences and outcome of melanoma patients

Cited by 4 publications

References 0 publications

A New Mathematical Model for Tumor Growth, Reduction and Metastasis, Validation with Zebrafish Melanoma and Potential Implications for Dormancy and Recurrence

A New Mathematical Model for Tumor Growth, Reduction and Metastasis, Validation with Zebrafish Melanoma and Potential Implications for Dormancy and Recurrence

Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials’ experience

The predictive factor for conjunctival melanoma recurrence

Contact Info

Product

Resources

About